CoChat

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Although many anticancer agents for gastric cancer have been developed, the prognosis for many patients remains poor. Recently, costimulatory immune molecules that reactivate antitumor immune responses by utilizing the host immune system have attracted attention as new therapeutic strategies. CD137 is a costimulatory molecule that reportedly potentiates the antitumor activity of tumor-targeting monoclonal antibodies (mAbs) by enhancing antibody-dependent cellular cytotoxicity. However, it remains unclear whether CD137 stimulates tumor-regulatory activity in gastric cancer. In this study, we investigated the antitumor effects of CD137 stimulation on gastric cancer cells administered tumor-targeting mAbs. Our results showed that human natural killer (NK) cells were activated by expressing CD137 after encountering trastuzumab-coated gastric cancer cells, and that stimulation of activated NK cells in the presence of trastuzumab and recombinant human CD137 ligand (rhCD137L) enhanced cytotoxicity and release of cytokines (IFN-γ, TNF, granzyme A, or granzyme B) as compared with activated NK cells with trastuzumab alone (p < 0.05). By combination treatment with rhCD137L, similar effects were obtained regarding cancer cell cytotoxicity in the presence of cetuximab (p < 0.01). Moreover, we revealed that CD137 expression was dependent upon the affinity between the Fc portion of the antibodies and FcγRIIIa of NK cells based on results indicating that human IgG1 and IgG3 subclasses enhanced CD137 expression (p < 0.001). These results confirmed that FcγRIIIA polymorphisms (158 V/V) enhanced CD137 expression to a greater degree than 158 F polymorphisms (p = 0.014). Our results suggested that CD137 stimulation could promote the effects of tumor-targeting mAbs in gastric cancer, and that further investigation of antibody binding affinity and in vivo activities might improve therapeutic strategies related to the treatment of gastric cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0204880

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 CD137 expression on NK cells following incubation of gastric cancer cells with trastuzumab. Purified NK cells from PBMCs of healthy individuals were analyzed for CD137 expression after 24-h culture with gastric cancer cell lines and trastuzumab. (A) HER2 expression on gastric cancer cell lines (TMK-1, NCI-N87, GLM-5S, and GLM-4). (B) CD137 expression on CD3-CD56+ NK cells from a representative healthy individual after 24-h culture with the respective gastric cancer cell lines in the presence or absence of trastuzumab. (C) Mean fluorescence intensity (MFI) of CD137 expression on NK cells from five healthy individuals cultured with the respective gastric cancer cell lines, * p < 0.001. Data are shown as the mean ± SEM.
Fig 1 CD137 expression on NK cells following incubation of gastric cancer cells with trastuzumab. Purified NK cells from PBMCs of healthy individuals were analyzed for CD137 expression after 24-h culture with gastric cancer cell lines and trastuzumab. (A) HER2 expression on gastric cancer cell lines (TMK-1, NCI-N87, GLM-5S, and GLM-4). (B) CD137 expression on CD3-CD56+ NK cells from a representative healthy individual after 24-h culture with the respective gastric cancer cell lines in the presence or absence of trastuzumab. (C) Mean fluorescence intensity (MFI) of CD137 expression on NK cells from five healthy individuals cultured with the respective gastric cancer cell lines, * p < 0.001. Data are shown as the mean ± SEM.CC BY · PubMed Central
Fig 2 Enhancement of trastuzumab-mediated NK cell cytotoxicity by rhCD137L. To evaluate NK cell cytotoxic function, purified NK cells from three healthy individuals were incubated with chromium-labeled tumor cells, including (A) GLM-4, (B) NCI-N87, and (C) TMK-1 for 18 h with medium alone, trastuzumab (10 ng/mL), or trastuzumab plus rhCD137L (250 ng/mL). The lysis percentages of the target cells cultured with medium alone (circles), trastuzumab (squares), or trastuzumab plus rhCD137L (triangles) according to chromium release at varying effector (NK cells):target-cell ratios are shown. (A, *p = 0.03; B, *p < 0.01; C, p = not significant). Data are shown as the mean ± SEM.
Fig 2 Enhancement of trastuzumab-mediated NK cell cytotoxicity by rhCD137L. To evaluate NK cell cytotoxic function, purified NK cells from three healthy individuals were incubated with chromium-labeled tumor cells, including (A) GLM-4, (B) NCI-N87, and (C) TMK-1 for 18 h with medium alone, trastuzumab (10 ng/mL), or trastuzumab plus rhCD137L (250 ng/mL). The lysis percentages of the target cells cultured with medium alone (circles), trastuzumab (squares), or trastuzumab plus rhCD137L (triangles) according to chromium release at varying effector (NK cells):target-cell ratios are shown. (A, *p = 0.03; B, *p < 0.01; C, p = not significant). Data are shown as the mean ± SEM.CC BY · PubMed Central
Fig 3 Increased cytokine secretion of trastuzumab-treated NK cells by rhCD137L administration. To investigate NK cell degranulation and cytokine secretion, NK cells were incubated with GLM-4 in the following four conditions: medium alone, trastuzumab (10 ng/mL), rhCD137L (250 ng/mL), or trastuzumab (10 ng/mL) with rhCD137L (250 ng/mL). (A) A representative flow cytometric plot of CD56 and CD107a double staining. Percentage and MFI of CD107a-expressing NK cells from five healthy individuals [p = not significant (NS)]. (B) Cytokine secretion (human IFN-γ, TNF, granzyme A, or granzyme B) determined by the cytometric bead array (*p < 0.005). Data are shown as the mean ± SEM.
Fig 3 Increased cytokine secretion of trastuzumab-treated NK cells by rhCD137L administration. To investigate NK cell degranulation and cytokine secretion, NK cells were incubated with GLM-4 in the following four conditions: medium alone, trastuzumab (10 ng/mL), rhCD137L (250 ng/mL), or trastuzumab (10 ng/mL) with rhCD137L (250 ng/mL). (A) A representative flow cytometric plot of CD56 and CD107a double staining. Percentage and MFI of CD107a-expressing NK cells from five healthy individuals [p = not significant (NS)]. (B) Cytokine secretion (human IFN-γ, TNF, granzyme A, or granzyme B) determined by the cytometric bead array (*p < 0.005). Data are shown as the mean ± SEM.CC BY · PubMed Central
Fig 4 Enhancement of cetuximab-mediated NK cell cytotoxicity by rhCD137L administration. Purified NK cells were analyzed for cytotoxicity with cetuximab (10 ng/mL) plus rhCD137L (250 ng/mL) in a chromium-release assay, as described previously. NK cells were incubated with gastric cell lines expressing high levels of EGFR [(A) MKN-1 and (B) MKN-45] or low levels of EGFR [(C) TMK-1] under the same conditions. Lysis percentages of the target cells cultured with medium alone (circles), cetuximab (squares), or cetuximab and rhCD137L (triangles) according to chromium release at varying effector (NK cells)/target-cell ratios are shown. (A, B, *p < 0.01; C, p = not significant). Data are shown as the mean ± SEM.
Fig 4 Enhancement of cetuximab-mediated NK cell cytotoxicity by rhCD137L administration. Purified NK cells were analyzed for cytotoxicity with cetuximab (10 ng/mL) plus rhCD137L (250 ng/mL) in a chromium-release assay, as described previously. NK cells were incubated with gastric cell lines expressing high levels of EGFR [(A) MKN-1 and (B) MKN-45] or low levels of EGFR [(C) TMK-1] under the same conditions. Lysis percentages of the target cells cultured with medium alone (circles), cetuximab (squares), or cetuximab and rhCD137L (triangles) according to chromium release at varying effector (NK cells)/target-cell ratios are shown. (A, B, *p < 0.01; C, p = not significant). Data are shown as the mean ± SEM.CC BY · PubMed Central
Fig 5 Upregulated CD137 expression and cytotoxicity of NK cells by treatment with a combination of trastuzumab and pertuzumab. (A) To evaluate upregulated CD137 expression in NK cells by treatment with the combination of dual anti-HER2 mAbs that bind different domains, purified NK cells were incubated with a HER2-expressing gastric cancer cell line (GLM-4) in medium containing various trastuzumab and pertuzumab concentrations (0–10 μg/mL) for 24 h. The MFI of CD137-expressing NK cells from three healthy individuals was analyzed by flow cytometry (*p < 0.05). Data are shown as the mean ± SEM. (B) Purified NK cells were analyzed for cytotoxicity in a chromium-release assay. Chromium-labeled GLM-4 cells and NK cells cultured with medium alone (circles), pertuzumab (white diamonds), trastuzumab (black diamonds), pertuzumab and trastuzumab (squares), or dual anti-HER2 mAbs and rhCD137L (triangles) are shown. (*p < 0.01). Data are shown as the mean ± SEM.
Fig 5 Upregulated CD137 expression and cytotoxicity of NK cells by treatment with a combination of trastuzumab and pertuzumab. (A) To evaluate upregulated CD137 expression in NK cells by treatment with the combination of dual anti-HER2 mAbs that bind different domains, purified NK cells were incubated with a HER2-expressing gastric cancer cell line (GLM-4) in medium containing various trastuzumab and pertuzumab concentrations (0–10 μg/mL) for 24 h. The MFI of CD137-expressing NK cells from three healthy individuals was analyzed by flow cytometry (*p < 0.05). Data are shown as the mean ± SEM. (B) Purified NK cells were analyzed for cytotoxicity in a chromium-release assay. Chromium-labeled GLM-4 cells and NK cells cultured with medium alone (circles), pertuzumab (white diamonds), trastuzumab (black diamonds), pertuzumab and trastuzumab (squares), or dual anti-HER2 mAbs and rhCD137L (triangles) are shown. (*p < 0.01). Data are shown as the mean ± SEM.CC BY · PubMed Central
Fig 6 Upregulated CD137 expression induced by incubation with immobilized IgG subclass. Purified NK cells were incubated for 24 h in the presence of immobilized IgG subclass (2 mg/mL), and CD137 expression was measured by flow cytometry. (A) CD137 expression on NK cells from a representative healthy individual after a 24-h culture. Percentages of CD137-expressing NK cells per quadrant are indicated. (B) MFI of CD137-expressing NK cells from five healthy individuals. **p < 0.001; *p = 0.016. Data are shown as the mean ± SEM.
Fig 6 Upregulated CD137 expression induced by incubation with immobilized IgG subclass. Purified NK cells were incubated for 24 h in the presence of immobilized IgG subclass (2 mg/mL), and CD137 expression was measured by flow cytometry. (A) CD137 expression on NK cells from a representative healthy individual after a 24-h culture. Percentages of CD137-expressing NK cells per quadrant are indicated. (B) MFI of CD137-expressing NK cells from five healthy individuals. **p < 0.001; *p = 0.016. Data are shown as the mean ± SEM.CC BY · PubMed Central
Fig 7 The influence of FcγRIIIa polymorphisms on trastuzumab-induced CD137 expression. Percentage of CD137-expressing NK cells from 38 healthy individuals after a 24-h incubation with trastuzumab-coated gastric cancer cells (GLM-4) exhibiting FcγRIIIa 158 polymorphism. CD137 presentation on NK cells was compared between V/V (n = 19) and F carriers (n = 19). F carriers were also divided into two groups: VF (n = 15, circles) and FF (n = 4, diamonds). *p = 0.014. Data are shown as the mean ± SEM.
Fig 7 The influence of FcγRIIIa polymorphisms on trastuzumab-induced CD137 expression. Percentage of CD137-expressing NK cells from 38 healthy individuals after a 24-h incubation with trastuzumab-coated gastric cancer cells (GLM-4) exhibiting FcγRIIIa 158 polymorphism. CD137 presentation on NK cells was compared between V/V (n = 19) and F carriers (n = 19). F carriers were also divided into two groups: VF (n = 15, circles) and FF (n = 4, diamonds). *p = 0.014. Data are shown as the mean ± SEM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Cited by

See all 13

Metadata

Authors
Misumi, T., Tanabe, K., Fujikuni, N., & Ohdan, H.
Affiliations
Hiroshima University (JP)
Corresponding author
Tanabe, Kazuaki
Venue
PLoS ONE
Published
2018-10-15
Volume
13
Issue
10
Pages
e0204880
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2896438622
Cited by
12
References
52
Citations by year
2025: 1 · 2024: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 1
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Hiroshima University Acedemic Information Repository (Hiroshima University) (submittedVersion, cc-by)
Funders
Japan Society for the Promotion of Science (25462023, 17K10591)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
4-1BB, natural killer cells, gastric cancer, trastuzumab, cetuximab, antibody-dependent cellular cytotoxicity, FcγRIIIa, FcγRIIIa polymorphism, costimulatory molecules, cytokine production, granzyme A, granzyme B, interferon-gamma, TNF-α
MeSH terms
Trastuzumab, Antineoplastic Agents, Immunological, Cell Survival, Drug Synergism, Female, Humans, Killer Cells, Natural, Recombinant Proteins, Stomach Neoplasms, Up-Regulation, Gene Expression Regulation, Neoplastic, Cytokines, Cell Line, Tumor, Cell Proliferation, 4-1BB Ligand, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.